EMBER-4: A Randomized, Open-Label, Phase 3 Study of
Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in 病人 who
have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+,
HER2- Early 乳腺癌 with an Increased Risk of Recurrence 阅读更多
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-肿瘤学 Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors 阅读更多
A011801 - THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), 一个双盲, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB 阅读更多
Neurocognitive changes in breast cancer patients on hormonal therapy. Is there a difference between objective and perceived neurocognition? 阅读更多
MammaPrint, 蓝图, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX) 阅读更多
